Erasca Added to the Nasdaq Biotechnology Index
Erasca, Inc. (Nasdaq: ERAS) has been added to the NASDAQ Biotech Index, effective December 20, 2021. This index tracks biotech and pharmaceutical companies listed on the Nasdaq, and membership requires meeting specific criteria, including market capitalization and trading volume. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers and is backed by experts in precision oncology. This inclusion indicates recognition of the company's growth and stability in the biotechnology sector.
- Inclusion in the NASDAQ Biotech Index enhances visibility and credibility.
- Strengthens Erasca's position and recognition in the biotechnology sector.
- None.
SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. Nasdaq selects all of the constituents of the index once annually in December.
For more information about the NASDAQ Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
